Transforming growth factor-p type

Okadome T, Oeda E, Saitoh M, Ichijo H, Moses HL, Miyazono K, Kawabata M. Characterization of the interaction of FKBP12 with the transforming growth factor-P type I receptor in vivo. Journal of Biological Chemistry 1996, 271, 21687-21690. 

Mutation analysis of the transforming growth factor P type II receptor in sporadic human cancers of the pancreas, liver, and breast. Biochem Biophys Res Commun, Vol. 223, No. 3, pp. 561-564, ISSN 0006-291X. 

Jin CH, Sreenu D, Krishnaiah M, Subrahmanyama VB, Rao KS, Mohan AVN, Park CY, Son JY, Son DH, Park HJ, Sheen YY, Kim DK (2011) Synthesis and biological evaluation of l-substituted-3(5)-(6-methylp5 ridin-2-yl)-4-(quinoxalin-6-yl)pyrazoles as transforming growth factor-p type 1 receptor kinase inhibitors. Eur J Med (Them 46(9) 3917-3925. doi 10.1016/j. ejmech.2011.05.063... 

Li F, Park Y, Hah JM, Ryu JS (2013b) Synthesis and biological evaluation of 1-(6-methylpyridin-2-yl)-5-(quinoxalin-6-yl)-l,2,3-triazoles as transforming growth factor-p type 1 receptor kinase inhibitors. Bioorg Med Chem Lett 23(4) 1083-1086. doi 10.1016/i.bmcl. 2012.12.008... 

Inhibition of human allergic T-helper type 2 immune responses by induced regulatory T cells requires the combination of interleukin- 10-treated dendritic cells and transforming growth factor-p for their induction. Clin Exp Allergy 2006 36 1546-1555. 

Fig. 6.5 Signalling through SMAD proteins. Receptor complexes, formed with transforming growth factor.p (TGF-p) and related factors, activins, and bone morphogenetic proteins (BMPs), consist of two serine/threonine receptor kinases, the type II and type I receptors. Binding of the ligand results In autophosphorylation of type I receptors. The activated type I receptors in turn phosphoryiate and activate R-SMADs SMADs 1,...

Rochester CL, Ackerman SJ, Zheng T, Elias JA. Eosinophil-fibroblast interactions. Granule major basic protein interacts with IL-1 and transforming growth factor-P in the stimulation of lung fibroblast IL-6-type cytokine production. J Immuno 1996 156 4449-56. 

Fig. 11.16. Serine/threonine receptors and Smad proteins. TGF-P (transforming growth factor P), which is composed of two identical subunits, communicates through a receptor dimer of type I and type II subunits that have serine kinase domains. The type I receptor phosphorylates an R-Smad (receptor-specific Smad), which binds a Co-Smad (common Smad, also called Smad 4).

Ohuchi, S. P., Ohtsu, T., Nakamura, Y. (2006). Selection of RNA aptamers against recombinant transforming growth factor-beta type III receptor displayed on cell surface. Biochimie 88, 897-904. 

R448 A. S. Patil, R. B. Sable and R. M. Kothari, An Update on Transforming Growth Factor-P (TGF-P) Sources, Types, Functions and Clinical Applicability for Cartilage/Bone Healing , J. Cell. Physiol., 2011, 226, 3084. 

Appling, W. D., O Brien, W. R., Johnston, D. A., and Duvic, M., 1989, Synergistic enhancement of type I and III collagen production in cultured fibroblasts by transforming growth factor-P and ascorbate, FEBS Lett. 250 541-544. 

---